Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 56, Issue 6, Pages 989-993Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2006.12.017
Keywords
-
Categories
Ask authors/readers for more resources
Background: Intralesional methotrexate (MTX) is an effective treatment for keratoacanthoma (KA). Objective: We sought to systematically examine response rates and adverse events in KA treated with intralesional MTX. Methods: All cases of KA treated with intralesional MTX at our institution from 1991 to 2006 were identified. A MEDLINE and PubMed search of cases of KA treated with intralesional MTX was also performed. Results: In all, 38 cases of KA treated with intralesional MTX were identified: 18 from our institution and 20 from the literature. Intralesional MTX achieved resolution in 92%, requiring an average of 2.1 injections an average of 18 days apart. Adverse events were rare, with two reports of pancytopenia in patients with chronic renal failure. Limitations: Use of single case reports, small series, and retrospective analysis are limitations. Conclusion: Intralesional MTX is a useful nonsurgical therapy for the treatment of KA. Histologic diagnosis before initiation of treatment is preferred. A complete blood cell count at baseline and during treatment should be considered to monitor for potential cytopenia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available